NO20064985L - Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer - Google Patents

Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer

Info

Publication number
NO20064985L
NO20064985L NO20064985A NO20064985A NO20064985L NO 20064985 L NO20064985 L NO 20064985L NO 20064985 A NO20064985 A NO 20064985A NO 20064985 A NO20064985 A NO 20064985A NO 20064985 L NO20064985 L NO 20064985L
Authority
NO
Norway
Prior art keywords
treatment
diagnostics
activated receptor
peroxisome proliferator
demyelinating diseases
Prior art date
Application number
NO20064985A
Other languages
English (en)
Norwegian (no)
Inventor
Anne Minnich
Jean Merrill
Olga Khorkova
Karen Chandross
Lan Lee
Yun Liu
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20064985L publication Critical patent/NO20064985L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20064985A 2004-04-01 2006-10-31 Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer NO20064985L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (1)

Publication Number Publication Date
NO20064985L true NO20064985L (no) 2006-10-31

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064985A NO20064985L (no) 2004-04-01 2006-10-31 Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer

Country Status (16)

Country Link
US (1) US20070149580A1 (https=)
EP (1) EP1737440A2 (https=)
JP (1) JP2007530703A (https=)
KR (1) KR20060134191A (https=)
CN (1) CN1950077A (https=)
AU (1) AU2005231358A1 (https=)
BR (1) BRPI0509540A (https=)
CA (1) CA2561159A1 (https=)
IL (1) IL178165A0 (https=)
MA (1) MA28561B1 (https=)
MX (1) MXPA06011218A (https=)
NO (1) NO20064985L (https=)
RU (1) RU2006138495A (https=)
SG (1) SG138623A1 (https=)
WO (1) WO2005097098A2 (https=)
ZA (1) ZA200607850B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1964575B1 (en) * 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8329725B2 (en) 2008-06-09 2012-12-11 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
KR20120107113A (ko) 2009-12-17 2012-09-28 사노피 수초 염기성 단백질 프로모터(ｍｂｐ-ｌｕｃｉ)의 조절 하에 루시페라제를 발현하는 동물 모델 및 생물발광 생체내 영상화를 위한 상기 동물 모델의 용도
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
WO2005097098A2 (en) 2005-10-20
BRPI0509540A (pt) 2007-09-18
MXPA06011218A (es) 2007-01-16
CN1950077A (zh) 2007-04-18
KR20060134191A (ko) 2006-12-27
JP2007530703A (ja) 2007-11-01
ZA200607850B (en) 2008-10-29
IL178165A0 (en) 2008-03-20
EP1737440A2 (en) 2007-01-03
CA2561159A1 (en) 2005-10-20
WO2005097098A3 (en) 2005-12-22
RU2006138495A (ru) 2008-05-10
US20070149580A1 (en) 2007-06-28
MA28561B1 (fr) 2007-04-03
SG138623A1 (en) 2008-01-28
AU2005231358A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
NO20064985L (no) Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer
US20230201032A1 (en) Method and device for treating an ocular disorder
Saraceno et al. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition
Hatzifotis et al. Hydrofluoric acid burns
US20140031845A1 (en) Method and device for treating an ocular disorder
Nelson et al. Venous leg ulcers
US20140214062A1 (en) Method and device for treating an ocular disorder
Kuo et al. Ultrasound-guided perineural injection with platelet-rich plasma improved the neurophysiological parameters of carpal tunnel syndrome: A case report
Xu et al. A critical assessment of the fibula flap donor site
Christie et al. Cross-frictional therapy and stretching for the treatment of palmar adhesions due to Dupuytren’s contracture: a prospective case study
Can Dupuytren’s contracture
Xu et al. Comparison between the efficacy of spinal cord stimulation and of endovascular revascularization in the treatment of diabetic foot ulcers: a retrospective observational study
Bigorre et al. Lateral epicondylitis treatment by extensor carpi radialis fasciotomy and radial nerve decompression: is outcome influenced by the occupational disease compensation aspect?
Kohorst et al. Treatment experience in a local population with hidradenitis suppurativa
Zhang et al. Study on the effect, safety, prognosis quality and application value of extracorporeal shock wave based neural activity in carpal tunnel syndrome patients
Lee et al. Functional improvement and scar impact of electromyography (EMG)-driven robotic training on nerve damage and hypertrophic scars in hands that underwent skin grafting after burns: a prospective, randomized, single-blinded study
RU2262962C2 (ru) Способ лечения компрессионно-ишемических невропатий
Poonsuk et al. Comparing treatment efficacy of court-type traditional Thai massage, elastic taping, and stretching for plantar fasciitis: a three-armed randomized controlled trial
Satyanarayana et al. OPEN REDUCTION AND INTERNAL FIXATION WITH PLATING VERSUS EXTERNAL FIXATOR IN DISTAL END RADIUS FRACTURES: A COMPARATIVE STUDY
RU2408322C1 (ru) Способ смещения нижней челюсти вниз для увеличения верхнего суставного пространства височно-нижнечелюстного сустава перед выполнением пункции сустава
Taheri et al. Radial extracorporeal shock wave therapy for Dupuytren's contracture: a case report
Zeinali et al. Comparison of the effects of kinesio taping to local injection of methyl prednisolone in treating brachial biceps tendonitis
Amouzegar et al. Onychogryphosis nails in a diabetic patient: Rare Case Report
Ramana et al. Efficacy of Therapeutic Ultrasound and Therapeutic Laser Along with Myofascial Release in Reducing Pain and Improving Hand Grip for People with Lateral Epicondylitis.
Shivachev et al. Oncology Rehabilitation-an alternative to breast cancer treatment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application